CliffBio
small molecule

POTASSIUM PHOSPHATES

POTASSIUM PHOSPHATE, DIBASIC; POTASSIUM PHOSPHATE, MONOBASIC

Loss of exclusivity—loss of exclusivity
CompanyCipla →See this company's full patent-cliff portfolio

Drug detail

Brand namePOTASSIUM PHOSPHATES
Active ingredientPOTASSIUM PHOSPHATE, DIBASIC; POTASSIUM PHOSPHATE, MONOBASIC
Strength11.8GM/50ML (236MG/ML);11.2GM/50ML (224MG/ML)
Dosage formSOLUTION
RouteINTRAVENOUS
ModalitySmall molecule
FDA approvalJanuary 2025
Marketing statusRX

More from Cipla

Source: FDA Orange Book, layered on the CliffBio company graph. Cliff dates are the loss of exclusivity; estimates are projections, not legal advice.

POTASSIUM PHOSPHATES patent cliff — loss of exclusivity — | CliffBio